In addition, the nanodevice has the advantage of binding to a broad range of thioredoxin interacting protein partners, which distinguish PCA associated stroma from that associated with benign tissue regions based on the inflammatory response and may not be seen using antibodies against any specific thioredoxin binding protein expressed in the stroma. This evidence concerns the gene TXN and posterior cortical atrophy.